The epidemiology and characteristics of patients with diabetes with or without NASH: a systematic review
- PMID: 38223606
- PMCID: PMC10782311
- DOI: 10.4314/ahs.v23i2.59
The epidemiology and characteristics of patients with diabetes with or without NASH: a systematic review
Abstract
Introduction: NASH or "Non-alcoholic Steatohepatitis" is related to non-alcoholic fatty liver disease (NAFLD). The simultaneous occurrence of NASH and type 2 diabetes is common. However, only a limited number of studies have focused on the characteristics of patients with diabetes with or without NASH.
Objectives: This systematic review summarises epidemiological evidence related to the prevalence and characteristics of NASH in patients with diabetes.
Methods: Different electronic databases PubMed, Scopus, and Google Scholar were searched for the published articles. Original studies conducted in patients with diabetes published in English were included in this review.
Results: Thirteen studies were eligible for inclusion in this review. In patients with diabetes, increased BMI, overweight/obesity, increased HbA1c, increased serum cholesterol, and elevated liver enzyme levels have been strongly linked with NASH. Other significant characteristics include increasing age, being female, race(white), low HDL, metformin use, increased ferritin, and increased albumin levels. The prevalence of NASH ranged from 12% to 93.8%, the highest percentage was found in studies in Romania (87.1), and lowest in studies in India (12.5).
Conclusion: The incidence of NASH increases with age. Gender differences as a risk factor for NASH still need to be fully understood. This systematic review provides insight and strong indication to all patients with diabetes to visit hepatologists and screen for fatty liver disease. If steatosis is found on baseline ultrasound, a liver biopsy should be performed for timely management. At present, no NAFLD/NASH-specific medication on the market helps in treating the disease. New development of the drugs and ongoing research is important for the cure and treatment of NASH, with specific attention being provided to involve populations at high-risk.
Keywords: NAFLD; NASH; diabetes mellitus; fatty liver; liver disease; non-alcoholic steatohepatitis; systematic review.
© 2023 Aldossari KK.
Figures
Similar articles
-
Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.BMC Gastroenterol. 2023 May 19;23(1):160. doi: 10.1186/s12876-023-02794-4. BMC Gastroenterol. 2023. PMID: 37208593 Free PMC article.
-
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.J Hepatol. 2019 Oct;71(4):793-801. doi: 10.1016/j.jhep.2019.06.021. Epub 2019 Jul 4. J Hepatol. 2019. PMID: 31279902
-
Non-alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects.Pediatr Diabetes. 2019 Feb;20(1):41-47. doi: 10.1111/pedi.12798. Epub 2018 Dec 9. Pediatr Diabetes. 2019. PMID: 30467936
-
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2023 Jan;8(1):20-30. doi: 10.1016/S2468-1253(22)00317-X. Epub 2022 Nov 16. Lancet Gastroenterol Hepatol. 2023. PMID: 36400097
-
Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.Curr Vasc Pharmacol. 2020;18(2):172-181. doi: 10.2174/1570161117666190405164313. Curr Vasc Pharmacol. 2020. PMID: 30961499 Review.
Cited by
-
Editor's choice: Covid-19 and HIV are still very much with us.Afr Health Sci. 2023 Jun;23(2):i-v. doi: 10.4314/ahs.v23i2.1. Afr Health Sci. 2023. PMID: 38223647 Free PMC article. No abstract available.
-
Salidroside may target PPARα to exert preventive and therapeutic activities on NASH.Front Pharmacol. 2024 Oct 2;15:1433076. doi: 10.3389/fphar.2024.1433076. eCollection 2024. Front Pharmacol. 2024. PMID: 39415834 Free PMC article.
References
-
- Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature reviews Gastroenterology & hepatology. 2018;15(1):11–20. - PubMed
-
- Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nature reviews Gastroenterology & hepatology. 2013;10(6):330. - PubMed
-
- Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. Journal of hepatology. 2017;67(6):1265–1273. - PubMed
-
- Ahmed A, Wong RJ, Harrison SA. Non-alcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. Clin Gastroenterol Hepatol. 2015;13(12):2062–2070. - PubMed
-
- Yki-Järvinen H. Diagnosis of non-alcoholic fatty liver disease (NAFLD) Diabetologia. 2016;59(6):1104–1111. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical